The ganglionic blocking properties of the cholinesterase reactivator, HS-6.
Following intravenous administration of the cholinesterase reactivator HS-6 (30 mg/kg), blood pressure fell (up to 50 mmHg) and maximal blood levels of HS-6 reached 242 microgram/ml. HS-6 attenuated the pressor response resulting from carotid occlusion and the depressor effect of vagal stimulation. Doses of HS-6 below those used to protect against soman in different animal species (10--30 mumol/kg) progressively blocked the ganglion-stimulating effects of nicotine and dimethylphenylpiperazinium but not the pressor effect following adrenaline, a pattern similar to that produced by hexamethonium but only 1/84 as potent. HS-6, like hexamethonium and mecamylamine, progressively blocked the contraction of the nictitating membrane of the cat resulting from preganglionic stimulation. The results indicate that HS-6 possesses ganglion-blocking properties at doses likely to be used in the protection against soman poisoning. The ganglion-blocking properties of the drug may be a factor in the beneficial effects of HS-6.
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D002801:Cholinesterase Reactivators / Q000097:blood / Q000494:pharmacology*; D004246:Dimethylphenylpiperazinium Iodide / Q000037:antagonists & inhibitors; D005727:Ganglia, Spinal / Q000187:drug effects; D005730:Ganglionic Blockers; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D009538:Nicotine / Q000037:antagonists & inhibitors; D009541:Nictitating Membrane / Q000187:drug effects; D011220:Pralidoxime Compounds / Q000097:blood / Q000494:pharmacology*
D002801:Cholinesterase Reactivators; D005730:Ganglionic Blockers; D011220:Pralidoxime Compounds; C003027:HS 6; D004246:Dimethylphenylpiperazinium Iodide; D009538:Nicotine